{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T18:50:41Z","timestamp":1781117441116,"version":"3.54.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40266-026-01292-y","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:28:07Z","timestamp":1773689287000},"page":"327-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-Vascular Endothelial Growth Factor Biosimilars for Use in the Aging Eye"],"prefix":"10.1007","volume":"43","author":[{"given":"Ashish","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay U.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch D.","family":"Kuppermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"2","key":"1292_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1292_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1258\/jrsm.2009.080298","volume":"102","author":"T Ayoub","year":"2009","unstructured":"Ayoub T, Patel N. Age-related macular degeneration. J R Soc Med. 2009;102(2):56\u201361. https:\/\/doi.org\/10.1258\/jrsm.2009.080298.","journal-title":"J R Soc Med"},{"issue":"4","key":"1292_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.survophthal.2024.08.003","volume":"70","author":"JU Sheth","year":"2025","unstructured":"Sheth JU, Stewart MW, Narayanan R, Anantharaman G, Chandran K, Lai TYY, et al. Macular neovascularization. Surv Ophthalmol. 2025;70(4):653\u201375. https:\/\/doi.org\/10.1016\/j.survophthal.2024.08.003.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"1292_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.e5. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018.","journal-title":"Ophthalmology"},{"issue":"14","key":"1292_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331. https:\/\/doi.org\/10.1056\/NEJMoa054481.","journal-title":"N Engl J Med"},{"issue":"12","key":"1292_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006.","journal-title":"Ophthalmology"},{"issue":"1","key":"1292_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017.","journal-title":"Ophthalmology"},{"issue":"8","key":"1292_CR8","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014.","journal-title":"Ophthalmology"},{"issue":"4","key":"1292_CR9","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","volume":"35","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N, Sadda SR, Corradetti G, Heier J, et al. Brolucizumab\u2014early real-world experience: BREW study. Eye (London). 2021;35(4):1045\u20137. https:\/\/doi.org\/10.1038\/s41433-020-1111-x.","journal-title":"Eye (London)"},{"key":"1292_CR10","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.2147\/OPTH.S395577","volume":"16","author":"D Chakraborty","year":"2022","unstructured":"Chakraborty D, Maiti A, Sheth JU, Mondal S, Boral S, Nandi K, et al. Brolucizumab in neovascular age-related macular degeneration\u2014Indian real-world experience: the BRAILLE study\u2014fifty-two-week outcomes. Clin Ophthalmol. 2022;16:4303\u201313. https:\/\/doi.org\/10.2147\/OPTH.S395577.","journal-title":"Clin Ophthalmol"},{"key":"1292_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2147\/OPTH.S521384","volume":"19","author":"V Agrawal","year":"2025","unstructured":"Agrawal V, Gupta A, Agrawal V, Sheth JU. Faricimab outcomes in chorioretinal disorders: Indian real-world analysis (FOCUS study). Clin Ophthalmol. 2025;19:1855\u201362. https:\/\/doi.org\/10.2147\/OPTH.S521384.","journal-title":"Clin Ophthalmol"},{"issue":"16","key":"1292_CR12","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/s41433-024-03220-z","volume":"38","author":"T Ueda-Consolvo","year":"2024","unstructured":"Ueda-Consolvo T, Ishida M, Nakamura T, Yanagisawa S, Tsuboi K, Wakabayashi T, et al. Biosimilar ranibizumab (BS1)\u2014early experience from Japan (BRIJ study). Eye (London). 2024;38(16):3193\u20136. https:\/\/doi.org\/10.1038\/s41433-024-03220-z.","journal-title":"Eye (London)"},{"issue":"5","key":"1292_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3928\/23258160-20210429-01","volume":"52","author":"R Narayanan","year":"2021","unstructured":"Narayanan R, Hariprasad SM, Sheth J. Biosimilars for the treatment of retinal diseases. Ophthalmic Surg Lasers Imaging Retina. 2021;52(5):242\u20136. https:\/\/doi.org\/10.3928\/23258160-20210429-01.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"1292_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ophtha.2021.09.008","volume":"129","author":"A Sharma","year":"2022","unstructured":"Sharma A, Kuppermann BD. Biosimilars for retinal diseases: understanding the phase 3 clinical trial design. Ophthalmology. 2022;129(1):65\u20136. https:\/\/doi.org\/10.1016\/j.ophtha.2021.09.008.","journal-title":"Ophthalmology"},{"key":"1292_CR15","unstructured":"Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Permission to manufacture and market ranibizumab solution for injection (r-DNA origin) (permission no: MF-35\/2015; BULK-36\/2015). Manufacturer Intas Pharmaceuticals Limited, Ahmedabad, Gujarat, India. 2013. https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=NTUzNg. Accessed 23 Jan 2026."},{"key":"1292_CR16","unstructured":"Generics and Biosimilars Initiative (GaBI). EC and FDA approval for first ranibizumab biosimilar Byooviz. 2021. https:\/\/www.gabionline.net\/biosimilars\/news\/ec-and-fda-approval-for-first-ranibizumab-biosimilar-byooviz. Accessed 23 Jan 2026."},{"issue":"2","key":"1292_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41433-022-02246-5","volume":"37","author":"A Sharma","year":"2023","unstructured":"Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab\u2014a global update. Eye (London). 2023;37(2):200\u20132. https:\/\/doi.org\/10.1038\/s41433-022-02246-5.","journal-title":"Eye (London)"},{"issue":"5","key":"1292_CR18","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s41433-021-01909-z","volume":"36","author":"A Sharma","year":"2022","unstructured":"Sharma A, Kumar N, Parachuri N, Loewenstein A, Bandello F, Kuppermann BD. On-label bevacizumab for retina: where it stands. Eye (London). 2022;36(5):916\u20137. https:\/\/doi.org\/10.1038\/s41433-021-01909-z.","journal-title":"Eye (London)"},{"issue":"5","key":"1292_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2025.2482663","volume":"25","author":"A Sharma","year":"2025","unstructured":"Sharma A, Woo SJ, Kuppermann BD. Aflibercept biosimilars\u2014so near, yet so far. Expert Opin Biol Ther. 2025;25(5):1\u20133. https:\/\/doi.org\/10.1080\/14712598.2025.2482663.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1292_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-34325-4","volume":"16","author":"JR Song","year":"2026","unstructured":"Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, et al. Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience\u2014ROSE Korea study. Sci Rep. 2026;16(1):4220. https:\/\/doi.org\/10.1038\/s41598-025-34325-4.","journal-title":"Sci Rep"},{"issue":"3","key":"1292_CR21","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40123-022-00507-w","volume":"11","author":"M Soman","year":"2022","unstructured":"Soman M, Nair I, Sheth JU, Nair U. Innovator versus biosimilar ranibizumab in polypoidal choroidal vasculopathy: real-world evidence. Ophthalmol Ther. 2022;11(3):1175\u201386. https:\/\/doi.org\/10.1007\/s40123-022-00507-w.","journal-title":"Ophthalmol Ther"},{"key":"1292_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251322213","author":"A Sharma","year":"2025","unstructured":"Sharma A, Holz FG, Kumar N, Sarraf D, Ayachit S, Mishra C, et al. Biosimilar ranibizumab (Ranieyes) safety and efficacy in the real world: BRESER study. J Vitreoretin Dis. 2025. https:\/\/doi.org\/10.1177\/24741264251322213.","journal-title":"J Vitreoretin Dis"},{"key":"1292_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101358","volume":"25","author":"A Sharma","year":"2022","unstructured":"Sharma A, Arunaprakash J, Das A, Nayaka A, Kumar N, Parachuri N, et al. Ranizurel safety evaluation in real-world (RaSER study). Am J Ophthalmol Case Rep. 2022;25:101358. https:\/\/doi.org\/10.1016\/j.ajoc.2022.101358.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"11","key":"1292_CR24","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1038\/s41433-025-03813-2","volume":"39","author":"S Avadzadeh","year":"2025","unstructured":"Avadzadeh S, Sharma A, Parvaresh MM, Ghasemi Falavarjani K, International Retina Biosimilar Study Group (Inter BIOS Group). Aflibercept 2 mg biosimilar (Tyalia)\u2014real-world experience from Iran (ATRIA study). Eye (Lond). 2025;39(11):2159\u201363. https:\/\/doi.org\/10.1038\/s41433-025-03813-2.","journal-title":"Eye (Lond)"},{"issue":"2","key":"1292_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/opo.12675","volume":"40","author":"TJ Heesterbeek","year":"2020","unstructured":"Heesterbeek TJ, Lor\u00e9s-Motta L, Hoyng CB, Lechanteur YTE, den Hollander AI. Risk factors for progression of age-related macular degeneration. Ophthalmic Physiol Opt. 2020;40(2):140\u201370. https:\/\/doi.org\/10.1111\/opo.12675.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"3","key":"1292_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4068\/cmj.2023.59.3.143","volume":"59","author":"MA Amini","year":"2023","unstructured":"Amini MA, Karbasi A, Vahabirad M, Khanaghaei M, Alizamir A. Mechanistic insight into age-related macular degeneration (AMD): anatomy, epidemiology, genetics, pathogenesis, prevention, implications, and treatment strategies to pace AMD management. Chonnam Med J. 2023;59(3):143\u201359. https:\/\/doi.org\/10.4068\/cmj.2023.59.3.143.","journal-title":"Chonnam Med J"},{"issue":"11","key":"1292_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biom12111629","volume":"12","author":"RH ElSheikh","year":"2022","unstructured":"ElSheikh RH, Chauhan MZ, Sallam AB. Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration. Biomolecules. 2022;12(11):1629. https:\/\/doi.org\/10.3390\/biom12111629.","journal-title":"Biomolecules"},{"key":"1292_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.preteyeres.2018.10.006","volume":"69","author":"T Van Bergen","year":"2019","unstructured":"Van Bergen T, Etienne I, Cunningham F, Moons L, Schlingemann RO, Feyen JHM, et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res. 2019;69:116\u201336. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.10.006.","journal-title":"Prog Retin Eye Res"},{"key":"1292_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1874364101307010004","volume":"7","author":"N Gupta","year":"2013","unstructured":"Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4\u201310. https:\/\/doi.org\/10.2174\/1874364101307010004.","journal-title":"Open Ophthalmol J"},{"issue":"4","key":"1292_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040926","volume":"10","author":"MG Dallinga","year":"2021","unstructured":"Dallinga MG, Habani YI, Schimmel AWM, Dallinga-Thie GM, van Noorden CJF, Klaassen I, et al. The role of heparan sulfate and neuropilin 2 in VEGFA signaling in human endothelial tip cells and non-tip cells during angiogenesis in vitro. Cells. 2021;10(4):926. https:\/\/doi.org\/10.3390\/cells10040926.","journal-title":"Cells"},{"issue":"7","key":"1292_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.4103\/ijo.IJO_992_16","volume":"65","author":"P Jain","year":"2017","unstructured":"Jain P, Sheth J, Anantharaman G, Gopalakrishnan M. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian J Ophthalmol. 2017;65(7):596\u2013602. https:\/\/doi.org\/10.4103\/ijo.IJO_992_16.","journal-title":"Indian J Ophthalmol"},{"issue":"9","key":"1292_CR32","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41433-020-0888-y","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Parachuri N, Kumar N, Sharma R, Bandello F, Kuppermann BD, et al. Brolucizumab\u2014another anti-VEGF or beyond. Eye (London). 2020;34(9):1499\u2013500. https:\/\/doi.org\/10.1038\/s41433-020-0888-y.","journal-title":"Eye (London)"},{"issue":"10326","key":"1292_CR33","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"issue":"20","key":"1292_CR34","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N Engl J Med"},{"issue":"14","key":"1292_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144671","volume":"12","author":"JG Garweg","year":"2023","unstructured":"Garweg JG, Keiper J, Pfister IB, Schild C. Functional outcomes of brolucizumab-induced intraocular inflammation involving the posterior segment\u2014a meta-analysis and systematic review. J Clin Med. 2023;12(14):4671. https:\/\/doi.org\/10.3390\/jcm12144671.","journal-title":"J Clin Med"},{"issue":"13","key":"1292_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132758","volume":"10","author":"A Bilgic","year":"2021","unstructured":"Bilgic A, Kodjikian L, March de Ribot F, Vasavada V, Gonzalez-Cortes JH, Abukashabah A, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med. 2021;10(13):2758. https:\/\/doi.org\/10.3390\/jcm10132758.","journal-title":"J Clin Med"},{"issue":"7-8","key":"1292_CR37","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1080\/09273948.2021.1931350","volume":"30","author":"A Sharma","year":"2022","unstructured":"Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Faricimab: two in the bush is proving better than one in the hand? Ocul Immunol Inflamm. 2022;30(7\u20138):1961\u20133. https:\/\/doi.org\/10.1080\/09273948.2021.1931350.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"1292_CR38","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1080\/10717544.2022.2069301","volume":"29","author":"SV Ranade","year":"2022","unstructured":"Ranade SV, Wieland MR, Tam T, Rea JC, Horvath J, Hieb AR, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Deliv. 2022;29(1):1326\u201334. https:\/\/doi.org\/10.1080\/10717544.2022.2069301.","journal-title":"Drug Deliv"},{"issue":"1","key":"1292_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40942-023-00446-z","volume":"9","author":"A Sharma","year":"2023","unstructured":"Sharma A, Khanani AM, Parachuri N, Kumar N, Bandello F, Kuppermann BD. Port delivery system with ranibizumab (Susvimo) recall\u2014what does it mean to retina specialists. Int J Retina Vitreous. 2023;9(1):6. https:\/\/doi.org\/10.1186\/s40942-023-00446-z.","journal-title":"Int J Retina Vitreous"},{"issue":"10436","key":"1292_CR40","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","volume":"403","author":"PA Campochiaro","year":"2024","unstructured":"Campochiaro PA, Avery R, Brown DM, Heier JS, Ho AC, Huddleston S, et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study. Lancet. 2024;403(10436):1563\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(24)00310-6.","journal-title":"Lancet"},{"issue":"5","key":"1292_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00296-016-3444-0","volume":"36","author":"E Mysler","year":"2016","unstructured":"Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36(5):613\u201325. https:\/\/doi.org\/10.1007\/s00296-016-3444-0.","journal-title":"Rheumatol Int"},{"issue":"1","key":"1292_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bjophthalmol-2019-314443","volume":"104","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br J Ophthalmol. 2020;104(1):2\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314443.","journal-title":"Br J Ophthalmol"},{"key":"1292_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-med-051215-031022","volume":"68","author":"LA Christl","year":"2017","unstructured":"Christl LA, Woodcock J, Kozlowski S. Biosimilars: the US regulatory framework. Annu Rev Med. 2017;68:243\u201354. https:\/\/doi.org\/10.1146\/annurev-med-051215-031022.","journal-title":"Annu Rev Med"},{"issue":"3","key":"1292_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16030321","volume":"16","author":"MA Cordeiro","year":"2024","unstructured":"Cordeiro MA, Vitorino C, Sinogas C, Sousa JJ. A regulatory perspective on biosimilar medicines. Pharmaceutics. 2024;16(3):321. https:\/\/doi.org\/10.3390\/pharmaceutics16030321.","journal-title":"Pharmaceutics"},{"issue":"12","key":"1292_CR45","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","volume":"114","author":"CF Kirchhoff","year":"2017","unstructured":"Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696\u2013705. https:\/\/doi.org\/10.1002\/bit.26438.","journal-title":"Biotechnol Bioeng"},{"key":"1292_CR46","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2147\/DDDT.S130318","volume":"11","author":"M Schiestl","year":"2017","unstructured":"Schiestl M, Zabransky M, S\u00f6rgel F. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways. Drug Des Dev Ther. 2017;11:1509\u201315. https:\/\/doi.org\/10.2147\/DDDT.S130318.","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"1292_CR47","first-page":"366","volume":"41","author":"MM Rumore","year":"2016","unstructured":"Rumore MM, Vogenberg FR. Biosimilars: still not quite ready for prime time. P T. 2016;41(6):366\u201375.","journal-title":"P T"},{"issue":"1","key":"1292_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/jpbs.JPBS_167_18","volume":"11","author":"BR Meher","year":"2019","unstructured":"Meher BR, Balan S, Mohanty RR, Jena M, Das S. Biosimilars in India: current status and future perspectives. J Pharm Bioallied Sci. 2019;11(1):12\u20135. https:\/\/doi.org\/10.4103\/jpbs.JPBS_167_18.","journal-title":"J Pharm Bioallied Sci"},{"issue":"2","key":"1292_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.4103\/ijo.IJO_2703_20","volume":"69","author":"JU Sheth","year":"2021","unstructured":"Sheth JU, Stewart MW, Khatri M, Gupta SR, Chawla S, Rajendran A, et al. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: insights from the Vitreoretinal Society of India biosimilars of anti-VEGF survey. Indian J Ophthalmol. 2021;69(2):352\u20136. https:\/\/doi.org\/10.4103\/ijo.IJO_2703_20.","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"1292_CR50","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14712598.2025.2506445","volume":"25","author":"A Sharma","year":"2025","unstructured":"Sharma A, Regillo CD, Nicholson L, Kumar N, Parachuri N, Wakabayashi T, et al. The conundrum of abundance: challenges of having too many biosimilars. Expert Opin Biol Ther. 2025;25(6):573\u20136. https:\/\/doi.org\/10.1080\/14712598.2025.2506445.","journal-title":"Expert Opin Biol Ther"},{"key":"1292_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1256542","volume":"14","author":"MA Pontes","year":"2024","unstructured":"Pontes MA, Ribeiro AA, Albuquerque FC, Leite Cotenzini SN. Comparative price analysis of biological medicines: disparities generated by different pricing policies. Front Pharmacol. 2024;14:1256542. https:\/\/doi.org\/10.3389\/fphar.2023.1256542.","journal-title":"Front Pharmacol"},{"issue":"11","key":"1292_CR52","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33451","volume":"4","author":"SR Dickson","year":"2021","unstructured":"Dickson SR, Kent T. Association of generic competition with price decreases in physician-administered drugs and estimated price decreases for biosimilar competition. JAMA Netw Open. 2021;4(11):e2133451. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.33451.","journal-title":"JAMA Netw Open"},{"key":"1292_CR53","unstructured":"Jeremias S. First ophthalmology biosimilar launches in US. Center for Biosimilars. Published June 2, 2022. https:\/\/www.centerforbiosimilars.com\/view\/first-lucentis-biosimilar-launches-in-us Accessed 23 Jan 2026."},{"issue":"10","key":"1292_CR54","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s40123-024-01011-z","volume":"13","author":"Y Yanagi","year":"2024","unstructured":"Yanagi Y, Takahashi K, Iida T, Gomi F, Onishi H, Morii J, et al. Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration and its subtypes from the societal and patient perspectives in Japan. Ophthalmol Ther. 2024;13(10):2629\u201344. https:\/\/doi.org\/10.1007\/s40123-024-01011-z.","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"1292_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ph18060908","volume":"18","author":"TG Bas","year":"2025","unstructured":"Bas TG. Innovative formulation strategies for biosimilars: trends focused on buffer-free systems, safety, regulatory alignment, and intellectual property challenges. Pharmaceuticals (Basel). 2025;18(6):908. https:\/\/doi.org\/10.3390\/ph18060908.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"1292_CR56","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","volume":"107","author":"NM Bressler","year":"2023","unstructured":"Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studni\u010dka J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2023;107(3):384\u201391. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319637.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1292_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","volume":"129","author":"FG Holz","year":"2022","unstructured":"Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54\u201363. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.031.","journal-title":"Ophthalmology"},{"key":"1292_CR58","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.2147\/OPTH.S473329","volume":"18","author":"S Chakraborty","year":"2024","unstructured":"Chakraborty S, Sheth JU. Efficacy and safety of an Indian bevacizumab biosimilar (BEVATAS) for retinal vein occlusion (BIOS-RVO study). Clin Ophthalmol. 2024;18:2865\u201371. https:\/\/doi.org\/10.2147\/OPTH.S473329.","journal-title":"Clin Ophthalmol"},{"key":"1292_CR59","unstructured":"Outlook Therapeutics Inc. Outlook Therapeutics announces UK MHRA marketing authorization for LYTENAVA (bevacizumab-vikg). GlobeNewsWire press release. 2024. https:\/\/ir.outlooktherapeutics.com\/node\/11681\/pdf Accessed 23 Jan 2026."},{"issue":"1","key":"1292_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001561","volume":"8","author":"SR Sadda","year":"2023","unstructured":"Sadda SR, Bradvica M, Vajas A, Sagong M, Ernest J, Studni\u010dka J, et al. Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial. BMJ Open Ophthalmol. 2023;8(1):e001561. https:\/\/doi.org\/10.1136\/bmjophth-2023-001561.","journal-title":"BMJ Open Ophthalmol"},{"issue":"7","key":"1292_CR61","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/jop.2025.0040","volume":"41","author":"H Lee","year":"2025","unstructured":"Lee H, Sharma A, Woo SJ. Clinical trials of aflibercept biosimilars: a review. J Ocul Pharmacol Ther. 2025;41(7):363\u20139. https:\/\/doi.org\/10.1089\/jop.2025.0040.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1292_CR62","unstructured":"Regeneron Pharmaceuticals Inc. Eylea HD (aflibercept) injection: highlights of prescribing information. Regeneron; 2023. https:\/\/www.regeneron.com\/products\/eylea-hd. Accessed 05 Feb 2026."},{"key":"1292_CR63","unstructured":"Drugs.com. When does Eylea patent expire? Updated 2024. https:\/\/www.drugs.com\/medical-answers\/eylea-patent-expire-3571144\/. Accessed 05 Feb 2026."},{"key":"1292_CR64","unstructured":"Clarivate. Drugs to watch: faricimab (Vabysmo). Clarivate Analytics; 2024. https:\/\/clarivate.com\/drugs-to-watch\/drugs-to-watch-listing\/faricimab\/ Accessed 05 Feb 2026."},{"key":"1292_CR65","unstructured":"Roche\/Genentech. Vabysmo (faricimab-svoa) prescribing information. Roche; 2022. https:\/\/www.gene.com\/medical-professionals\/medicines\/vabysmo. Accessed 05 Feb 2026."},{"key":"1292_CR66","unstructured":"CliniVal (Clival). Brolucizumab patent expiry analysis. Clival; 2024. https:\/\/clival.com. Accessed 05 Feb 2026."},{"key":"1292_CR67","unstructured":"Novartis Pharmaceuticals Corporation. Beovu (brolucizumab-dbll) prescribing information. Novartis; 2019. https:\/\/www.novartis.com\/our-products\/beovu. Accessed 05 Feb 2026."},{"key":"1292_CR68","unstructured":"U.S. Food and Drug Administration. Biosimilar development, review, and approval. FDA; 2023. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-development-review-and-approval. Accessed 05 Feb 2026."},{"issue":"8","key":"1292_CR69","first-page":"469","volume":"6","author":"EA Blackstone","year":"2013","unstructured":"Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469\u201378.","journal-title":"Am Health Drug Benefits"},{"issue":"10","key":"1292_CR70","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s41433-022-02287-w","volume":"37","author":"A Sharma","year":"2023","unstructured":"Sharma A, Kumar N, Parachuri N, Regillo C, Bandello F, Kuppermann BD. Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians? Eye (London). 2023;37(10):1953\u20134. https:\/\/doi.org\/10.1038\/s41433-022-02287-w.","journal-title":"Eye (London)"},{"issue":"6","key":"1292_CR71","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40259-020-00446-7","volume":"34","author":"DF Alvarez","year":"2020","unstructured":"Alvarez DF, Wolbink G, Cronenberger C, Orazem J, Kay J. Interchangeability of biosimilars: what level of clinical evidence is needed to support the interchangeability designation in the United States? BioDrugs. 2020;34(6):723\u201332. https:\/\/doi.org\/10.1007\/s40259-020-00446-7.","journal-title":"BioDrugs"},{"key":"1292_CR72","unstructured":"U.S. Food and Drug Administration. FDA updates guidance on interchangeability. Silver Spring (MD): U.S. Food and Drug Administration; 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-guidance-interchangeability. Accessed 23 Jan 2026."},{"key":"1292_CR73","unstructured":"U.S. Food and Drug Administration. Purple Book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. Published February 2026. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/purple-book-lists-licensed-biological-products-reference-product-exclusivity-and-biosimilarity-or. Accessed 23 Jan 2026."},{"issue":"11","key":"1292_CR74","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41433-022-02117-z","volume":"36","author":"A Sharma","year":"2022","unstructured":"Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD. Fear of safety compromise with biosimilar anti-VEGF\u2014perception or truth. Eye (London). 2022;36(11):2086\u20137. https:\/\/doi.org\/10.1038\/s41433-022-02117-z.","journal-title":"Eye (London)"},{"issue":"e1","key":"1292_CR75","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1136\/ejhpharm-2021-002955","volume":"30","author":"MA Calleja","year":"2023","unstructured":"Calleja MA, Albanell J, Aranda E, Garc\u00eda-Foncillas J, Feliu A, Rivera F, et al. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. Eur J Hosp Pharm. 2023;30(e1):e40\u20137. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002955.","journal-title":"Eur J Hosp Pharm"},{"issue":"4","key":"1292_CR76","first-page":"3","volume":"7","author":"AW Mulcahy","year":"2018","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.","journal-title":"Rand Health Q."},{"key":"1292_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"1292_CR78","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jamaophthalmol.2021.1037","volume":"139","author":"A Sharma","year":"2021","unstructured":"Sharma A, Kumar N, Parachuri N. Biosimilar ranibizumab (SB11) vs reference ranibizumab\u2014diving deeper for safety and efficacy. JAMA Ophthalmol. 2021;139(6):677\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.1037.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"1292_CR79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","volume":"141","author":"NM Bressler","year":"2023","unstructured":"Bressler NM, Kim T, Oh I, Russo P, Kim MY, Woo SJ. Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and reference product Lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase 3 randomized clinical trial. JAMA Ophthalmol. 2023;141(2):117\u201327. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.5403.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"1292_CR80","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40123-021-00345-2","volume":"10","author":"D Chakraborty","year":"2021","unstructured":"Chakraborty D, Stewart MW, Sheth JU, Sinha TK, Boral S, Das A, et al. Real-world safety outcomes of intravitreal ranibizumab biosimilar (Razumab) therapy for chorioretinal diseases. Ophthalmol Ther. 2021;10(2):337\u201348. https:\/\/doi.org\/10.1007\/s40123-021-00345-2.","journal-title":"Ophthalmol Ther"},{"issue":"17","key":"1292_CR81","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41433-024-03284-x","volume":"38","author":"A Sharma","year":"2024","unstructured":"Sharma A, Kaiser PK, Tadayoni R, Holz FG, Nicholson L, Vazquez-Alfageme C, et al. Anti-VEGF biosimilars for retinal diseases survey 2023\u2014India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI). Eye (London). 2024;38(17):3392\u20135. https:\/\/doi.org\/10.1038\/s41433-024-03284-x.","journal-title":"Eye (London)"},{"issue":"4","key":"1292_CR82","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463\u201378. https:\/\/doi.org\/10.1007\/s40265-018-0881-y.","journal-title":"Drugs"},{"key":"1292_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.756633","volume":"9","author":"D Montano","year":"2022","unstructured":"Montano D. Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European Union and the United States. Front Public Health. 2022;9:756633. https:\/\/doi.org\/10.3389\/fpubh.2021.756633.","journal-title":"Front Public Health"},{"issue":"6","key":"1292_CR84","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","volume":"8","author":"C Boudousq","year":"2024","unstructured":"Boudousq C, Nguyen V, Hunt A, Gillies M, Zarranz-Ventura J, O\u2019Toole L, et al. European unmet needs in the management of neovascular age-related macular degeneration in daily practice: data from the Fight Retinal Blindness! registry. Ophthalmol Retina. 2024;8(6):527\u201336. https:\/\/doi.org\/10.1016\/j.oret.2024.01.004.","journal-title":"Ophthalmol Retina."},{"key":"1292_CR85","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2147\/OPTH.S180393","volume":"12","author":"A Sharma","year":"2018","unstructured":"Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: is there a big change on the horizon? Clin Ophthalmol. 2018;12:2137\u201343. https:\/\/doi.org\/10.2147\/OPTH.S180393.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"1292_CR86","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40259-024-00659-0","volume":"38","author":"C Rieger","year":"2024","unstructured":"Rieger C, Dean JA, Hall L, Vasquez P, Merlo G. Barriers and enablers affecting the uptake of biosimilar medicines viewed through the lens of actor network theory: a systematic review. BioDrugs. 2024;38(4):541\u201355. https:\/\/doi.org\/10.1007\/s40259-024-00659-0.","journal-title":"BioDrugs"},{"issue":"8","key":"1292_CR87","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.18553\/jmcp.2021.27.8.1129","volume":"27","author":"BS Edgar","year":"2021","unstructured":"Edgar BS, Cheifetz AS, Helfgott SM, Smith GP, Bandekar T, Hoye-Simek A, et al. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm. 2021;27(8):1129\u201335. https:\/\/doi.org\/10.18553\/jmcp.2021.27.8.1129.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"1292_CR88","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41433-019-0722-6","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Bandello F, Loewenstein A, Kuppermann BD. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye (London). 2020;34(6):1006\u20137. https:\/\/doi.org\/10.1038\/s41433-019-0722-6.","journal-title":"Eye (London)"},{"issue":"125","key":"1292_CR89","doi-asserted-by":"publisher","first-page":"22","DOI":"10.56920\/cehj.835","volume":"37","author":"M Cano","year":"2025","unstructured":"Cano M, Dhanapala M, Kang M, Piyasena MP, Raman R, Yorston D. Biosimilars for anti-VEGF treatment of macular diseases: country and region reports. Community Eye Health J. 2025;37(125):22\u20133. https:\/\/doi.org\/10.56920\/cehj.835.","journal-title":"Community Eye Health J"},{"issue":"1","key":"1292_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00343-3","volume":"8","author":"M Kapur","year":"2022","unstructured":"Kapur M, Nirula S, Naik MP. Future of anti-VEGF: biosimilars and biobetters. Int J Retina Vitreous. 2022;8(1):2. https:\/\/doi.org\/10.1186\/s40942-021-00343-3.","journal-title":"Int J Retina Vitreous"},{"issue":"5","key":"1292_CR91","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1586\/17469899.2013.840095","volume":"8","author":"MR Kudelka","year":"2013","unstructured":"Kudelka MR, Grossniklaus HE, Mandell KJ. Emergence of dual VEGF and PDGF antagonists in the treatment of exudative age-related macular degeneration. Expert Rev Ophthalmol. 2013;8(5):475\u201384. https:\/\/doi.org\/10.1586\/17469899.2013.840095.","journal-title":"Expert Rev Ophthalmol"},{"issue":"2","key":"1292_CR92","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/APO.0000000000000570","volume":"12","author":"A Arrigo","year":"2023","unstructured":"Arrigo A, Aragona E, Bandello F. The role of inflammation in age-related macular degeneration: updates and possible therapeutic approaches. Asia Pac J Ophthalmol. 2023;12(2):158\u201367. https:\/\/doi.org\/10.1097\/APO.0000000000000570.","journal-title":"Asia Pac J Ophthalmol"},{"issue":"7","key":"1292_CR93","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41433-019-0391-5","volume":"33","author":"A Sharma","year":"2019","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Biologics, biosilimars, and biobetters: different terms or different drugs? Eye (London). 2019;33(7):1032\u20134. https:\/\/doi.org\/10.1038\/s41433-019-0391-5.","journal-title":"Eye (London)"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01292-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:49:49Z","timestamp":1774964989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01292-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01292-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"AS reports consultancy relationships with Oculis, Novartis, Allergan, Bayer, Lupin, Intas, Ajanta, and Sun Pharma, and speaker fees from MS Pharma, Abdi \u0130brahim \u0130la\u00e7 San. ve Tic, and Samil Pharma. JS declares no competing interests. BDK reports clinical research support from Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, and ThromboGenics, and consultancy roles with Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, and Theravance Biopharma.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"AS contributed to conception, analysis, drafting, integrity checks, and final approval of the manuscript. JS and BDK contributed to drafting, critical revision, analysis, and integrity checks. All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}